Reliability of Automated Amyloid PET Quantification: Real-World Validation of Commercial Tools Against Centiloid Project Method.

Tomography

Division of Nuclear Medicine, Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

Published: July 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Despite the growing demand for amyloid PET quantification, practical challenges remain. As automated software platforms are increasingly adopted to address these limitations, we evaluated the reliability of commercial tools for Centiloid quantification against the original Centiloid Project method. This retrospective study included 332 amyloid PET scans (165 [F]Florbetaben; 167 [F]Flutemetamol) performed for suspected mild cognitive impairments or dementia, paired with T1-weighted MRI within one year. Centiloid values were calculated using three automated software platforms, BTXBrain, MIMneuro, and SCALE PET, and compared with the original Centiloid method. The agreement was assessed using Pearson's correlation coefficient, the intraclass correlation coefficient (ICC), a Passing-Bablok regression, and Bland-Altman plots. The concordance with the visual interpretation was evaluated using receiver operating characteristic (ROC) curves. BTXBrain (R = 0.993; ICC = 0.986) and SCALE PET (R = 0.992; ICC = 0.991) demonstrated an excellent correlation with the reference, while MIMneuro showed a slightly lower agreement (R = 0.974; ICC = 0.966). BTXBrain exhibited a proportional underestimation (slope = 0.872 [0.860-0.885]), MIMneuro showed a significant overestimation (slope = 1.053 [1.026-1.081]), and SCALE PET demonstrated a minimal bias (slope = 1.014 [0.999-1.029]). The bias pattern was particularly noted for FMM. All platforms maintained their trends for correlations and biases when focusing on subthreshold-to-low-positive ranges (0-50 Centiloid units). However, all platforms showed an excellent agreement with the visual interpretation (areas under ROC curves > 0.996 for all). Three automated platforms demonstrated an acceptable reliability for Centiloid quantification, although software-specific biases were observed. These differences did not impair their feasibility in aiding the image interpretation, as supported by the concordance with visual readings. Nevertheless, users should recognize the platform-specific characteristics when applying diagnostic thresholds or interpreting longitudinal changes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12389775PMC
http://dx.doi.org/10.3390/tomography11080086DOI Listing

Publication Analysis

Top Keywords

amyloid pet
12
scale pet
12
pet quantification
8
commercial tools
8
tools centiloid
8
centiloid project
8
project method
8
automated software
8
software platforms
8
centiloid quantification
8

Similar Publications

Background: Plasma p-tau181 has proven to be a promising diagnostic and prognostic tool in the earliest phases of Alzheimer's disease (AD). We aimed to evaluate the prognostic role of p-tau181 in predicting conversion to AD dementia and worsening in cognition in mild cognitive impairment (MCI) and subjective cognitive decline (SCD).

Methods: We consecutively enrolled 163 patients (50 SCD, 70 MCI, and 43 AD-demented (AD-d)), who underwent plasma p-tau181 analysis with the Simoa assay.

View Article and Find Full Text PDF

Objective: The objective of this study was to determine the predictive value of amyloid-positron emission tomography (PET) versus the plasma ratio of phosphorylated tau at threonine 217 (p-tau217) to non-phosphorylated tau217 (%p-tau217) for tau-PET transitions (T- to T+). The added value of combining plasma amyloid-β 42 and amyloid-β 40 (Aβ42/40) and %p-tau217 into an amyloid probability score (APS2) was also assessed.

Methods: Mayo Clinic Study of Aging (MCSA) participants had plasma markers measured at via mass spectrometry (MS), an amyloid-PET scan, and a tau-PET (meta-temporal region of interest [ROI]) negative scan (standardized uptake value ratio [SUVR] <1.

View Article and Find Full Text PDF

Introduction: We developed and validated age-related amyloid beta (Aβ) positron emission tomography (PET) trajectories using a statistical model in cognitively unimpaired (CU) individuals.

Methods: We analyzed 849 CU Korean and 521 CU non-Hispanic White (NHW) participants after propensity score matching. Aβ PET trajectories were modeled using the generalized additive model for location, scale, and shape (GAMLSS) based on baseline data and validated with longitudinal data.

View Article and Find Full Text PDF

Importance: It is unclear whether the duration of amyloid-β (Aβ) pathology is associated with neurodegeneration and whether this depends on the presence of tau.

Objective: To examine the association of longitudinal atrophy with Aβ positron emission tomography (PET)-positivity (Aβ+) and the estimated duration of Aβ+ (Aβ+ duration), controlling for tau-positivity.

Design, Setting, And Participants: Data for this longitudinal cohort study were drawn from the Wisconsin Registry for Alzheimer Prevention and the Wisconsin Alzheimer Disease Research Center Clinical Core Study.

View Article and Find Full Text PDF

Background Elevated brain iron is a potential marker for neurodegeneration, but its role in predicting onset of mild cognitive impairment (MCI) and prospective cognitive trajectories remains unclear. Purpose To investigate how brain iron and amyloid-β (Aβ) levels, measured using quantitative susceptibility mapping (QSM) MRI and PET, help predict MCI onset and cognitive decline. Materials and Methods In this prospective study conducted between January 2015 and November 2022, cognitively unimpaired older adults underwent baseline QSM MRI.

View Article and Find Full Text PDF